日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Pharmacokinetic bioequivalence of the fixed-dose combination of pertuzumab and trastuzumab administered subcutaneously using a handheld syringe or an on-body delivery system

使用手持注射器或体外给药系统皮下注射帕妥珠单抗和曲妥珠单抗固定剂量组合的药代动力学生物等效性

期刊:Journal of Cancer Research and Clinical Oncology
影响因子:2.8
doi:10.1007/s00432-025-06228-4
Wynne, Chris; Wang, Bei; Deng, Rong; Li, Junyi; Eiger, Daniel; Bene Tchaleu, Fabiola; Heeson, Sarah; Restuccia, Eleonora
发表日期：2025
文献求助 收藏

heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer

heredERA乳腺癌：一项III期、随机、开放标签研究，旨在评估giredestrant联合固定剂量帕妥珠单抗和曲妥珠单抗皮下注射治疗既往未接受治疗的HER2阳性、雌激素受体阳性局部晚期或转移性乳腺癌患者的疗效和安全性。

期刊:BMC Cancer
影响因子:3.4
doi:10.1186/s12885-024-12179-9
Kuemmel, Sherko; Harper-Wynne, Catherine; Park, Yeon Hee; Franke, Fábio; de Laurentiis, Michelino; Schumacher-Wulf, Eva; Eiger, Daniel; Heeson, Sarah; Cardona, Andrés; Özyilkan, Özgür; Morales-Vàsquez, Flavia; Metcalfe, Ciara; Hafner, Marc; Restuccia, Eleonora; O'Shaughnessy, Joyce
肿瘤
HER2
肿瘤免疫
信号转导
乳腺癌
免疫/内分泌
发表日期：2024
文献求助 收藏

Pertuzumab, trastuzumab, and chemotherapy in HER2-positive gastric/gastroesophageal junction cancer: end-of-study analysis of the JACOB phase III randomized clinical trial

帕妥珠单抗、曲妥珠单抗和化疗治疗 HER2 阳性胃癌/胃食管交界处癌：JACOB III 期随机临床试验的最终分析

期刊:Gastric Cancer
影响因子:5.1
doi:10.1007/s10120-022-01335-4
Tabernero, Josep; Hoff, Paulo M; Shen, Lin; Ohtsu, Atsushi; Shah, Manish A; Siddiqui, Asna; Heeson, Sarah; Kiermaier, Astrid; Macharia, Harrison; Restuccia, Eleonora; Kang, Yoon-Koo
胃癌
肿瘤
肿瘤免疫
HER2
发表日期：2023
文献求助 收藏

Development of a Subcutaneous Fixed-Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose-Finding Study

帕妥珠单抗和曲妥珠单抗皮下固定剂量组合制剂的研发：Ib期剂量探索研究结果

期刊:Journal of Clinical Pharmacology
影响因子:2.3
doi:10.1002/jcph.1362
Kirschbrown, Whitney P; Wynne, Chris; Kågedal, Matts; Wada, Russ; Li, Hanbin; Wang, Bei; Nijem, Ihsan; Badovinac Crnjevic, Tanja; Gasser, Helena; Heeson, Sarah; Eng-Wong, Jennifer; Garg, Amit
发表日期：2019
文献求助 收藏

RM-025: Chemoradiation for unresectable gall bladder cancer: regional cancer centre study

RM-025：不可切除胆囊癌的放化疗：区域癌症中心研究

期刊:Annals of Oncology
影响因子:65.4
doi:10.1093/annonc/mdy538
Swain, S M; Schneeweiss, A; Gianni, L; Gao, J J; Stein, A; Waldron-Lynch, M; Heeson, S; Beattie, M S; Yoo, B; Cortes, J; Baselga, J; Kostov, D; Bounedjar, A; Sadykov, R; Kumari, P; Khatri, P; Singhal, M
肿瘤
肿瘤免疫
胆囊癌
发表日期：2016
文献求助 收藏

An intragenic methylated region in the imprinted Igf2 gene augments transcription

印迹基因 Igf2 中的基因内甲基化区域增强转录

期刊:EMBO Reports
影响因子:6.2
doi:10.1093/embo-reports/kve248
Murrell, A; Heeson, S; Bowden, L; Constância, M; Dean, W; Kelsey, G; Reik, W
表观遗传
WB
发表日期：2001
文献求助 收藏